| Hans-Günter Meyer-Thompson | Buprenorphin
Burprenorphin: Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence
Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence
Lund, Sweden — Camurus (NASDAQ STO: CAMX) today announced the company’s Marketing Authorization Application (MAA) for the investigational, weekly and monthly CAM2038 buprenorphine depots for the treatment of opioid dependence has been fully validated by the European Medicines Agency (EMA). The application, submitted on 26 July 2017, is now under assessment by the Committee for Human Medicinal Products (CHMP). (Camurus, Pressemitteilung –> Press Releases -> Archive, 20.09.2017)